BioLife Solutions(NASDAQ) BLFS

BioLife Solutions, Inc. helps scientists keep living cells healthy. These tools help doctors safely prepare therapies for patients. The company focuses on the cell and gene medicine field.

Protecting Cells From Lab to Patient

• Biopreservation Media: Proprietary liquids like HypoThermosol FRS and CryoStor that protect cells from damage during storage.
• Automated Thawing: Devices under the ThawSTAR brand that use controlled heat to safely warm frozen biological materials.
• Cell Processing: Tools including human platelet lysate media, cryogenic vials, and machines used to fill vials during manufacturing.

Acquisitions and New Directions

• Entered into a merger agreement with Repligen on July 21, 2026, to become a wholly owned subsidiary.
• Acquired the remaining 90% of PanTHERA CryoSolutions on April 4, 2025, to gain patented cryopreservation technology.
• Sold the SAVSU smart shipping container business on Oct. 6, 2025, to focus on bioproduction tools.

Innovation in Cryobiology

BioLife maintains expertise in cryobiology to reduce cell death during the manufacturing and transport of genetic therapies. The company serves researchers across the United States, Europe, the Middle East, and Africa using a global distributor network.

The Numbers Behind the Growth

• Total revenue reached $28.5 million for the three months ended June 30, 2026, up 21% year over year.
• Revenue for the six-month period ended June 30, 2026, was $56.0 million, up 23% year over year.
• Gross margin was 64% for the six-month period ended June 30, 2026, down 2% year over year.
• Cash and liquid securities totaled $113.1 million as of June 30, 2026.

Bottom Line

BioLife has evolved from a tool provider into a specialized partner for the cell and gene therapy industry. Its upcoming merger with Repligen marks a shift toward becoming part of a larger life sciences platform.